drugset / Trial / NCT02380235
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad of population of children.
Timeline
- Start
- 2014-12
- Primary completion
- 2017-06
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEG-somatropin | Protein / enzyme biologic | 0.12 mg/kg | — |
| Subject | PEG-somatropin | Protein / enzyme biologic | 0.2 mg/kg | — |